Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK001 in Neovascular Age-Related Macular Degeneration
NCT03021785Phase 1Unknown
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sevacizumab in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Frequency of ocular and systemic Adverse Events (AEs) and Serious Adverse Events (SAEs) at 40 weeks. Status: unknown.
02
Drugs
sevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03021785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021785.